Nuvation Bio INC 10-Q quarterly reports

Nuvation Bio Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing product revenue from IBTROZI, increased operating expenses, and a substantial accumulated deficit, while also announcing a significant convertible senior notes offering.

Nuvation Bio Inc. reported increased revenues and a strengthened cash position for Q3 2025, driven by the commercial launch of IBTROZI in the U.S. and regulatory approvals in Japan and China.

Nuvation Bio reports significant revenue growth driven by the U.S. launch of IBTROZI and a strengthened financial position following a $200 million non-dilutive financing.

Nuvation Bio reports Q1 2025 financial results, highlighting revenue growth from collaborative agreements and progress in clinical development programs.

Nuvation Bio's Q3 2024 report details a significant net loss driven by acquired R&D, alongside progress in clinical trials and a key NDA submission.

Nuvation Bio's second quarter results for 2024 reflect the impact of the AnHeart Therapeutics acquisition, including a significant charge for acquired in-process research and development.

Nuvation Bio reports a net loss of $14.8 million for the first quarter of 2024, with a focus on advancing its oncology pipeline and integrating the recent acquisition of AnHeart Therapeutics.